Search Results - "Booth, C.M."

Association between the time to surgery and survival among patients with colon cancer: A population-based study by Flemming, J.A, Nanji, S, Wei, X, Webber, C, Groome, P, Booth, C.M

“…Abstract Factors associated with time-to-surgery (TTS) and survival in colon cancer has not been well studied. Cancer Care Ontario recommends surgery within 42…”
Get full text

Curative Therapy for Bladder Cancer in Routine Clinical Practice: A Population-based Outcomes Study by Booth, C.M, Siemens, D.R, Li, G, Peng, Y, Kong, W, Berman, D.M, Mackillop, W.J

“…Abstract Aims Definitive therapy of bladder cancer involves cystectomy or radiotherapy; controversy exists regarding optimal management. Here we describe the…”
Get full text

Prognosis, Treatment Benefit and Goals of Care: What do Oncologists Discuss with Patients who have Incurable Cancer? by Raskin, W, Harle, I, Hopman, W.M, Booth, C.M

“…Abstract Aims Documentation of advance directives among patients with terminal cancer is known to be poor. Here we describe documentation of prognosis,…”
Get full text

Adjuvant Chemotherapy for Stage II Colon Cancer: Practice Patterns and Effectiveness in the General Population by Booth, C.M, Nanji, S, Wei, X, Peng, Y, Biagi, J.J, Hanna, T.P, Krzyzanowska, M.K, Mackillop, W.J

“…Abstract Aims Although guidelines do not recommend adjuvant chemotherapy (ACT) for stage II colon cancer, many state that ACT may be considered in high-risk…”
Get full text

Chemotherapy Delivery for Resected Colorectal Cancer Liver Metastases: Management and Outcomes in Routine Clinical Practice by Krishnamurthy, Anuradha, Kankesan, Janarthanan, Wei, Xuejiao, Nanji, Sulaiman, Biagi, James J, Booth, Christopher M., Dr

“…Abstract Background International guidelines recommend peri-operative chemotherapy for patients with resectable colorectal cancer liver metastases (CRCLM)…”
Get full text

Patterns of Referral to Radiation Oncology among Patients with Bladder Cancer: a Population-based Study by Quirt, J.S, Siemens, D.R, Zaza, K, Mackillop, W.J, Booth, C.M

“…Abstract Aims Radical radiotherapy is a reasonable alternative to cystectomy for some patients with invasive bladder cancer, and postoperative radiotherapy may…”
Get full text

Surgical resection and peri-operative chemotherapy for colorectal cancer liver metastases: A population-based study by Booth, C.M, Nanji, S, Wei, X, Biagi, J.J, Krzyzanowska, M.K, Mackillop, W.J

“…Abstract Background Most literature describing surgery for colorectal cancer (CRC) liver metastases (LM) comes from high volume centres. Here, we report…”
Get full text

1334P Objective response rates of placebo in randomized controlled trials of anticancer medicines: 2015 – 2019 by Sachdev, A., Sharpe, I., Bowman, M., Gyawali, B., Booth, C.M.

Get full text

How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy by Fundytus, A., Booth, C.M., Tannock, I.F.

Get full text

ESMO Guidance for Reporting Oncology real-World evidence (GROW) by Castelo-Branco, L, Pellat, A, Martins-Branco, D, Valachis, A, Derksen, J W G, Suijkerbuijk, K P M, Dafni, U, Dellaporta, T, Vogel, A, Prelaj, A, Groenwold, R H H, Martins, H, Stahel, R, Bliss, J, Kather, J, Ribelles, N, Perrone, F, Hall, P S, Dienstmann, R, Booth, C M, Pentheroudakis, G, Delaloge, S, Koopman, M

Get more information

Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit? by Del Paggio, J.C., Azariah, B., Sullivan, R., Hopman, W.M., James, F.V., Roshni, S., Tannock, I.F., Booth, C.M.

“…The European Society for Medical Oncology (ESMO) recently released a magnitude of clinical benefit scale (ESMO-MCBS) for systemic therapies for solid cancers…”
Get full text

First-line Palliative Chemotherapy for Colorectal Cancer: a Population-based Analysis of Delivery and Outcomes in a Single-payer Health System by Wilson, B E, Booth, C M, Patel, S, Berry, S, Kong, W, Merchant, S J

“…Clinical practice guidelines recommend palliative chemotherapy for most patients with metastatic colorectal cancer. However, outcomes observed in the real…”
Get full text

Five years of EMA-approved systemic cancer therapies for solid tumours—a comparison of two thresholds for meaningful clinical benefit by Grössmann, N., Del Paggio, J.C., Wolf, S., Sullivan, R., Booth, C.M., Rosian, K., Emprechtinger, R., Wild, C.

“…Several societies have proposed frameworks to evaluate the benefit of oncology drugs; one prominent tool is the European Society for Medical Oncology Magnitude…”
Get full text

Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and Interpretation by Fundytus, A., Wells, J.C., Sharma, S., Hopman, W.M., Del Paggio, J.C., Gyawali, B., Mukherji, D., Hammad, N., Pramesh, C.S., Aggarwal, A., Sullivan, R., Booth, C.M.

“…Most randomised controlled trials (RCTs) in oncology are now funded by the pharmaceutical industry. We explore the extent to which RCT design, results and…”
Get full text

A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma by Hanna, T.P., Nguyen, P., Baetz, T., Booth, C.M., Eisenhauer, E.

“…New targeted drugs and immune therapies reported since 2010 for metastatic or unresectable melanoma (MM) have shown improved survival in randomised trials. We…”
Get full text

Venous Thromboembolism During Chemotherapy for Testicular Cancer: A Population-Based Study by Robinson, A.G., Wei, X., Karim, S., Raphael, M.J., Bedard, P.L., Booth, C.M.

“…Venous thromboembolism (VTE) is a potential complication among germ cell tumour patients. We evaluated the incidence rate, timing and factors associated with…”
Get full text

Neurotoxicity Among Survivors of Testicular Cancer: A Population-based Study by Raphael, M.J., Wei, X., Karim, S., Robinson, A.G., Bedard, P.L., Booth, C.M.

“…Neurotoxicity may affect the quality of life of survivors of testicular cancer. Understanding the burden of neurotoxicity is important to guide survivorship…”
Get full text

Re-aligning the ASCO and ESMO clinical benefit frameworks for modern cancer therapies by Del Paggio, J.C., Sullivan, R., Hopman, W.M., Booth, C.M.

Get full text

Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2-positive Oesophageal, Gastroesophageal and Gastric Cancer by Merchant, S.J., Kong, W., Gyawali, B., Hanna, T., Chung, W., Nanji, S., Patel, S.V., Booth, C.M.

“…In the pivotal Trastuzumab for Gastric Cancer (ToGA) trial, trastuzumab improved median survival in patients with advanced HER-2-positive gastric and…”
Get full text

Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points by Kay, A., Higgins, J., Day, A.G., Meyer, R.M., Booth, C.M.

“…We previously reported metrics of systemic therapy randomized controlled trials (RCTs) in breast cancer, colorectal cancer (CRC), and non-small-cell lung…”
Get full text